|Description||This active molecular is a potent Prostaglandin D2 receptor antagonists and has been in phase I clinical trials for both COPD (chronic obstructive pulmonary disease) and asthma, but no recent results has been published.|
|Solubility||Soluble in DMSO|
|Application||chronic obstructive pulmonary disease(COPD) and asthma|
|Quality Standard||In-house standard|
|Shelf Life||2 month in rt, long time|
|Current Developer||Panmira Pharmaceuticals|
(+)-Cloprostenol sodium salt
(+)-Cloprostenol sodium salt is the d-enantiomer of Cloprostenol, which is an aryl-oxymethyl analog of prostaglandin F2α. It has luteolytic effects and is used ...
This active molecular is a prostaglandin receptor agonist and detailed information has not been published yet.
MF592 is a potent and selective antagonists of the EP4 receptor. It has good functional potency and potent inhibition of PGE2 modulated TNFa release in LPS stim...
OC000459 is a potent and selective D prostanoid receptor 2 (DP2) antagonist with IC50 of 13 nM.
Ifetroban is a selective Prostaglandin receptor and Thromboxane A2 receptor antagonist under the development of Bristol-Myers Squibb. Phase II clinical trials f...
Misoprostol, a synthetic analog of natural prostaglandin E1, is an effective anti-ulcer agent and also has oxytocic properties.
This active molecular is a potent Prostaglandin D2 receptor antagonists and has been in phase I clinical trials for both COPD (chronic obstructive pulmonary dis...
Mf-63 is a selective Microsomal prostaglandin E2 synthase-1 (mPGES-1) inhibitor. Its IC50 value is 0.9 nM and 1.3 nM for pig mPGES-1 and human mPGES-1 enzyme, r...
CP-533536, also called as Evatanepag, a 3-pyridyl sulfonamide compound, demonstrated excellent in vitro potency against prostaglandin E2 (PGE2) (induces local b...
MK-2894 Na salt
The sodium salt form of MK-2894 that is found to have conceivable potency and selectivity for further study and might be safer than traditional Non-steroidal an...
A EP1 antagonist (pKi= 7.54) (pIC50= 8.5)
E7046 is an orally bioavailable and specific type 4 prostaglandin E2 (PGE2) receptor EP antagonist (IC50= 13.5 nM) (Ki= 23.14 nM), with anti-tumor activities.
CP 544326, also known as taprenepag, is a potent and selective EP(2) receptor agonist. Its EC50 value is 2.8 nM. It is the active acid metabolite of the prodrug...
ONO-AE3-208 is an EP4 antagonist (Ki values are 1.3, 30, 790 and 2400 nM for EP4, EP3, FP and TP receptors respectively), which less potently affects EP3, FP, a...
GW 627368X is a potent and selective competitive antagonist of the EP4 receptor with additional human TP receptor affinity (Ki values of 100 nM and 158 nM, resp...
PF-04418948 is a potent and selective prostaglandin EP₂ receptor antagonist with IC50 of 16 nM. Phase 1. PF-04418948 antagonizes the effects of butaprost and PG...
Ethamsylate is a haemostatic drug, which inhibits biosynthesis and action of prostaglandins, and increases capillary endothelial resistance as and platelet adhe...
GSK-345931A is an EP(1) receptor antagonist. It is efficient in preclinical models of inflammatory pain.
PF-04217329 is a potent and selective EP2 receptor agonist on intraocular pressure in preclinical models of glaucoma. It is a prodrug of CP-544326. It is well t...
Cloprostenol sodium is a synthetic and water-soluble aryl-oxymethyl analog of prostaglandin F2α. lt is also a potent inhibitor of rat adipose precursor differen...